Should You Buy Vericel Corp (VCEL) Stock on Wednesday?

Overall market sentiment has been high on Vericel Corp (VCEL) stock lately. VCEL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Vericel Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VCEL!

See Full VCEL Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With VCEL Stock Today?

Vericel Corp (VCEL) stock is trading at $37.74 as of 11:23 AM on Wednesday, Nov 15, a rise of $0.99, or 2.69% from the previous closing price of $36.75. The stock has traded between $36.58 and $38.17 so far today. Volume today is less active than usual. So far 55,760 shares have traded compared to average volume of 322,324 shares. To see InvestorsObserver's Sentiment Score for Vericel Corp click here.

More About Vericel Corp

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. Click Here to get the full Stock Report for Vericel Corp stock.